强生10.5亿美元卖他喷他多美国权利给Depomed

Johnson & Johnson agrees to sell US rights to Nucynta franchise to Depomed for $1.05 billion

(Ref: Johnson & Johnson, CNBC, The Wall Street Journal, Bloomberg, StreetInsider, NASDAQ, Depomed)

January 15th, 2015

By: Joe Barber

Tags: Top Story Nucynta Depomed Grunenthal J&J Corporate Affairs Licensing Marketing & Sales

Johnson & Johnson's Janssen Pharmaceuticals unit reached an agreement to sell the US rights to its pain therapy Nucynta (tapentadol), including Nucynta ER and Nucynta oral solution, to Depomed for$1.05 billion, the companies announced Thursday. The all-cash deal is expected to close in the second quarter.

强生杨森制药单元日前达成一项协议，以10.5亿美元将其包括Nucynta ER与Nucynta口服溶液在内的疼痛治疗药物他喷他多（Nucynta）美国权利出售给Depomed，两家公司如是称。这项全现金交易有望于今年第二季度交割。

"We believe that Nucynta is an ideal strategic fit for Depomed – a rare opportunity to add a proprietary, differentiated drug with a lengthy period of exclusivity that fits precisely into our therapeutic focus," remarked Depomed chief executive Jim Schoeneck. The company stated that the transaction will be immediately accretive.

“我们认为，他喷他多对Depomed来说是一个理想的战略协调性，这是一个难得的增添一款拥有知识产权、有区别药物的机会，这款产品漫长的独占性恰好符合我们的治疗重点，”Depomed首席执行官Schoeneck评论称。该公司称，这项交易会迅速为公司带来增值。

Depomed indicated that it plans to expand its sales force to more than 250 people as part of its efforts to re-introduce Nucynta and promote the therapy for both chronic pain and nerve damage caused by diabetes. The drugmaker noted that the drug, which amassed US revenue of about $166 million for the 12 months ended September 2014, has patent protection until 2022, with the possibility of a paediatric extension until the following year.

Depomed指出，该公司计划将其销售队伍扩大到逾250人，作为努力的一部分重新推广Nucynta，促使这款治疗药物既用于慢性疼痛也用于糖尿病引起的神经损伤。该制药商指出，这款药物的专利保护期到2022年，而用于儿科的可能性会让其专利保护扩展到2023年，这款药物截止到2014年9月份，其在美国12个月的销售估计有1.66亿美元。

Meanwhile, Johnson & Johnson will retain rights to the product in other markets, including Canada and Japan. In 2010, the drugmaker expanded its licensing agreement for the therapy with Grunenthal to include selected countries in Asia, Latin America, Africa and Europe.

与此同时，强生将保留这款产品在其它市场，包括加拿大及日本的权利。2010年，该制药商针对这款治疗药物扩大了其与Grunenthal的许可协议，包括了亚洲、拉丁美洲、非洲及欧洲选择的一些国家。